SLC5A1 and hypertrophic cardiomyopathy: In addition, Hirose et al. (2018) demonstrated that SGLT1 knockout effectively alleviated pressure-overload–induced cardiomyopathy, suggesting that SGLT1 inhibitors have an active effect on hypertrophic cardiomyopathy.